Fuelled by an increasing disease awareness, the growing use of new, expensive drugs as well as combination therapy, the HBV drugs market, sized at $431m in 2006 across the seven major markets, will nearly triple in size by 2016. Rapid growth until 2011 will slow down in the following years as a result of genericization and the beginning impact of routine HBV vaccination.

Scope

In-depth analysis of the current hepatitis B market situation across the major Western markets Thorough assessment of underlying commercial and clinical influencers shaping the hepatitis B market Detailed sales forecasts for key hepatitis B drug classes, molecules and brands in each of the seven major markets In-depth discussion of novel hepatitis B pipeline candidates and assessment of their future potential

Highlights

Due to their good safety profile and increasing efficacy, antivirals will expand their lead as the dominant drug class for HBV treatment. Particularly Bristol-Myer Squibb's Baraclude (entecavir) will experience a rapid uptake. Interferons will benefit from increased diagnosis rates and combination therapy, but their overall use will remain limited. Launch of Gilead's tenofovir, already marketed for HIV and currently in Phase III trials for HBV, is expected for 2008. Driven by its excellent efficacy, safety and resistance profile, tenofovir will replace entecavir as the market leader by 2013, reaching peak sales of up to $400m across the 7MM. HBV vaccination is becoming increasingly established across the 7MM, but its impact is mitigated by immigration from areas of high disease prevalence. Merck & Co and GSK currently dominate this market. Therapeutic vaccines offer hope for a cure, but are a long way from approval.

Reasons to Purchase

Review the clinical and commercial factors driving new product decisions in hepatitis B, and the opportunities and threats facing the market Gain insight through a detailed sales forecast and a thorough analysis of marketed and pipeline products Understand where concerns, unmet needs and future opportunities lie by learning about the views of key hepatitis B opinion leaders.